Bildkälla: Stockfoto

Xbrane Biopharma Q1 2023: A transformational quarter - Redeye

Redeye provides its view on Xbrane following its Q1 2023 report, which included the notable milestone of Ximluci’s first-ever sales.

Redeye provides its view on Xbrane following its Q1 2023 report, which included the notable milestone of Ximluci’s first-ever sales.
Börsvärldens nyhetsbrev
ANNONSER